Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Turcot syndrome 1Stomach Neoplasms 1Pancreatic Neoplasms 1Oligoprogressive 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Head and Neck Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Cancer Patients 1

Interventions

Gemcitabine 33Cisplatin 28pembrolizumab 19durvalumab 17Oxaliplatin 16Fluorouracil 16Leucovorin 14Magnetic Resonance Spectroscopy 13Biopsy 10Specimen Handling 9lenvatinib 7Nivolumab 7Capecitabine 7Taxes 6Paclitaxel 6Irinotecan 6fludarabine 5Folfox protocol 5Drug Therapy 5Carboplatin 5Albumin-Bound Paclitaxel 5pemigatinib 4Ipilimumab 4Fluorodeoxyglucose F18 4Floxuridine 4Cyclophosphamide 4Bevacizumab 4130-nm albumin-bound paclitaxel 4tremelimumab 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × DEAE-Dextran × 1 year × Clear all
NCT07291947 2025-12-18

PULSAR Combined With Immunotherapy and Chemotherapy

West China Hospital

Phase 1/2 Recruiting
60 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡